#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Drug eruption Deafness neurosensory Multifocal motor neuropathy Pyruvate kinase deficiency anaemia Fibrosarcoma Kidney transplant rejection Growth hormone deficiency Human papilloma virus immunisation Ovarian cancer stage III Skin angiosarcoma Congenital ectodermal dysplasia Waldenstrom's macroglobulinaemia recurrent Gastroenteropancreatic neuroendocrine tumour disease Non-small cell lung cancer metastatic Neuroendocrine tumour More trials…

    Learn about Rare Diseases

    Antithrombin III deficiency – Life with Disease Bronchopulmonary dysplasia – Basic Information Haemolytic uraemic syndrome – Basic Information Nodal marginal zone B-cell lymphoma – Basic Information Systemic sclerosis pulmonary – Diagnostics Mitochondrial myopathy – Treatment Hairy cell leukaemia recurrent – Diagnostics Behcet’s syndrome – Life with Disease Ewing’s sarcoma metastatic – Life with Disease Rett syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Imatinib Mesilate [18F]-Altanserin Haloperidol Elvn-002-1 Placebo Vortioxetine Berotralstat Melphalan Flufenamide Paracetamol Dc [89Zr]Bms-986279 Mebendazole Quercus Robur Pollen Extract Liraglutide Gozetotide Alf-18 Caraway Oil Tumor Necrosis Factor-Alpha Canis Familiaris (553) Acetylcysteine Amide Doxorubicin Tigulixostat More therapies…

    Learn about Your Condition

    Bronchitis Pulmonary resection Eye disorder Febrile neutropenia Ophthalmoplegia Richter's syndrome Mucopolysaccharidosis III Extra-osseous Ewing's sarcoma Cystic fibrosis Vascular graft thrombosis Albuminuria Wiskott-Aldrich syndrome Post procedural swelling Infective uveitis Schizoaffective disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. KBC Zagreb

KBC Zagreb

Ulica Mije Kispatica 12, Zagreb, 10000, Croatia

Want to learn more about this study or check if you can participate? Contact us.

  • A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

    Recruiting

    2 1
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ampicillin Sodium
    • POLYMYXIN B SULFATE
    • Rifabutin
    Croatia Greece

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

    Recruiting

    3 1
    Investigated Drugs:
    • Remibrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +19

  • A study to evaluate the safety of dazodalibep in patients with Sjögren’s Syndrome over a long period of time

    Recruiting

    3 1 1
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ranibizumab
    Austria Belgium Bulgaria Croatia Czechia France +7

  • A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +10

  • Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Allogenic stem cell transplantation
    Investigated Drugs:
    • Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit
    • Blinatumomab
    • Busulfan
    Austria Belgium Croatia Czechia Denmark Finland +10

  • A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Belzutifan
    • Cabozantinib
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    Austria Belgium Croatia Czechia Denmark France +6
1 2 3 … 16
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!